Heather Greenlee1,2, Dawn L Hershman1,2,3, Zaixing Shi1, Marilyn L Kwan4, Isaac J Ergas4, Janise M Roh4, Lawrence H Kushi4. 1. Mailman School of Public Health, Columbia University, New York, NY, USA. 2. Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA. 3. College of Physicians and Surgeons, Columbia University, New York, NY, USA. 4. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Abstract
Background: Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer. Methods: Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25 kg/m2; overweight: 25-29.9 kg/m2; obese: ≥30 kg/m2), moderate-to-vigorous physical activity (MVPA) (low: <2.5; medium: 2.5-5; high: >5 hours/week) and fruit/vegetable intake (low: <35 servings/week; high: ≥35 servings/week). Baseline and six-month interviews assessed antioxidant supplement use (nonuser, discontinued, continued user, initiator). CIPN was assessed at baseline, six months, and 24 months using the Functional Assessment of Cancer Therapy-Taxane Neurotoxicity (FACT-NTX); a 10% decrease was considered clinically meaningful. Results: At baseline, 65.6% of patients in the sample were overweight or obese, 29.9% had low MVPA, 57.5% had low fruit/vegetable intake, and 9.5% reported antioxidant supplement use during treatment. In multivariable analyses, increased CIPN was more likely to occur in overweight (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.19 to 4.88) and obese patients (OR = 3.21, 95% CI = 1.52 to 7.02) compared with normal weight patients at 24 months and less likely to occur in patients with high MVPA compared with those with low MVPA at six (OR = 0.56, 95% CI = 0.34 to 0.94) and 24 months (OR = 0.43, 95% CI = 0.21 to 0.87). Compared with nonusers, patients who initiated antioxidant use during treatment were more likely to report increased CIPN at six months (OR = 3.81, 95% CI = 1.82 to 8.04). Conclusions: Obesity and low MVPA were associated with CIPN in breast cancer patients who received taxane treatment.
Background: Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer. Methods: Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25 kg/m2; overweight: 25-29.9 kg/m2; obese: ≥30 kg/m2), moderate-to-vigorous physical activity (MVPA) (low: <2.5; medium: 2.5-5; high: >5 hours/week) and fruit/vegetable intake (low: <35 servings/week; high: ≥35 servings/week). Baseline and six-month interviews assessed antioxidant supplement use (nonuser, discontinued, continued user, initiator). CIPN was assessed at baseline, six months, and 24 months using the Functional Assessment of Cancer Therapy-Taxane Neurotoxicity (FACT-NTX); a 10% decrease was considered clinically meaningful. Results: At baseline, 65.6% of patients in the sample were overweight or obese, 29.9% had low MVPA, 57.5% had low fruit/vegetable intake, and 9.5% reported antioxidant supplement use during treatment. In multivariable analyses, increased CIPN was more likely to occur in overweight (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.19 to 4.88) and obese patients (OR = 3.21, 95% CI = 1.52 to 7.02) compared with normal weight patients at 24 months and less likely to occur in patients with high MVPA compared with those with low MVPA at six (OR = 0.56, 95% CI = 0.34 to 0.94) and 24 months (OR = 0.43, 95% CI = 0.21 to 0.87). Compared with nonusers, patients who initiated antioxidant use during treatment were more likely to report increased CIPN at six months (OR = 3.81, 95% CI = 1.82 to 8.04). Conclusions: Obesity and low MVPA were associated with CIPN in breast cancer patients who received taxane treatment.
Authors: Dawn L Hershman; Louis H Weimer; Antai Wang; Grace Kranwinkel; Lois Brafman; Deborah Fuentes; Danielle Awad; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2010-12-03 Impact factor: 4.872
Authors: Patricia M Kluding; Mamatha Pasnoor; Rupali Singh; Stephen Jernigan; Kevin Farmer; Jason Rucker; Neena K Sharma; Douglas E Wright Journal: J Diabetes Complications Date: 2012-06-18 Impact factor: 2.852
Authors: Marilyn L Kwan; Christine B Ambrosone; Marion M Lee; Janice Barlow; Sarah E Krathwohl; Isaac Joshua Ergas; Christine H Ashley; Julie R Bittner; Jeanne Darbinian; Keren Stronach; Bette J Caan; Warren Davis; Susan E Kutner; Charles P Quesenberry; Carol P Somkin; Barbara Sternfeld; John K Wiencke; Shichun Zheng; Lawrence H Kushi Journal: Cancer Causes Control Date: 2008-05-14 Impact factor: 2.506
Authors: F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz Journal: Ann Oncol Date: 2014-02 Impact factor: 32.976
Authors: Heather Greenlee; Marilyn L Kwan; Isaac J Ergas; Garrett Strizich; Janise M Roh; Allegra T Wilson; Marion Lee; Karen J Sherman; Christine B Ambrosone; Dawn L Hershman; Alfred I Neugut; Lawrence H Kushi Journal: BMC Cancer Date: 2014-05-29 Impact factor: 4.430
Authors: Dawn L Hershman; Joseph M Unger; Katherine D Crew; Cathee Till; Heather Greenlee; Lori M Minasian; Carol M Moinpour; Danika L Lew; Louis Fehrenbacher; James L Wade; Siu-Fun Wong; Michael J Fisch; N Lynn Henry; Kathy S Albain Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Lara Sánchez-Barroso; Maria Apellaniz-Ruiz; Gerardo Gutiérrez-Gutiérrez; María Santos; Juan M Roldán-Romero; Maria Curras; Laura Remacha; Bruna Calsina; Isabel Calvo; María Sereno; María Merino; Jesús García-Donas; Beatriz Castelo; Eva Guerra; Rocio Letón; Cristina Montero-Conde; Alberto Cascón; Lucía Inglada-Pérez; Mercedes Robledo; Cristina Rodríguez-Antona Journal: Oncologist Date: 2018-11-23
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Susan Storey; Andrea Cohee; Diane Von Ah; Eric Vachon; Noah R Zanville; Patrick O Monahan; Timothy E Stump; Victoria L Champion Journal: J Patient Cent Res Rev Date: 2020-10-23
Authors: Gary R Zirpoli; Susan E McCann; Lara E Sucheston-Campbell; Dawn L Hershman; Gregory Ciupak; Warren Davis; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; G Thomas Budd; Kathy S Albain; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2017-12-01 Impact factor: 13.506
Authors: Elizabeth M Cespedes Feliciano; Valerie S Lee; Carla M Prado; Jeffrey A Meyerhardt; Stacey Alexeeff; Candyce H Kroenke; Jingjie Xiao; Adrienne L Castillo; Bette J Caan Journal: Cancer Date: 2017-09-07 Impact factor: 6.860
Authors: Mark K Greenwald; Julie J Ruterbusch; Jennifer L Beebe-Dimmer; Michael S Simon; Terrance L Albrecht; Ann G Schwartz Journal: Cancer Date: 2018-11-02 Impact factor: 6.860
Authors: Rikki A Cannioto; Alan Hutson; Shruti Dighe; William McCann; Susan E McCann; Gary R Zirpoli; William Barlow; Kara M Kelly; Carol A DeNysschen; Dawn L Hershman; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; Kathy S Albain; G Thomas Budd; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2021-01-04 Impact factor: 13.506